AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

Contributed by: PR Newswire

Tags

AbbVie-VENCLYXTO®

More Like This

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

PATIENTS ACROSS ENGLAND AND WALES GAIN ACCESS TO NEW TREATMENT OPTION FOR MANTLE CELL LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING POSITIVE NICE DECISIONS

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

PR Newswire associated0

EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma